Distribution and prognostic validity of the new global initiative for chronic obstructive lung disease grading classification

Chest

Volumn 143, Issue 3, 2013, Pages 694-702

  Soriano, Joan B ^a   Alfageme, Inmaculada ^b   Almagro, Pere ^c   Casanova, Ciro ^d   Esteban, Cristobal ^e   Soler Cataluña, Juan J ^f   De Torres, Juan P ^g   Martinez Camblor, Pablo ^h   Miravitlles, Marc ⁱ   Celli, Bartolome R ^j   Marin, Jose M ^k  

^a Epidemiology and Clinical Research   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^e HOSPITAL DE GALDAKAO   (Spain)

^f HOSPITAL GENERAL DE REQUENA   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h UNIVERSITY OF OVIEDO   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HARVARD UNIVERSITY   (United States)

^k HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; C STATISTICS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SPIROMETRY; STATISTICAL ANALYSIS; SURVIVAL; SYMPTOM; VALIDATION STUDY;

EID: 84874969178     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1053     Document Type: Article

References (33)

1. Calverley PM. The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med. 2004; 170 (3): 211-212.
2. Global strategy for the diagnosis, management and prevention of COPD. 2011. Global Initiative for Chronic Obstructive Lung Disease (GOLD) website. http://www.goldcopd.org/. Accessed March 8, 2011.
3. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest. 2008; 133 (1): 19-25.
4. Rabe KF, Hurd S, Anzueto A, et al Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176 (6): 532-555.
5. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999; 28 (1): 1-9.
6. Esteban C, Quintana JM, Aburto M, et al. Predictors of mortality in patients with stable COPD. J Gen Intern Med. 2008; 23 (11): 1829-1834.
7. de Torres JP, Bastarrika G, Zagaceta J, et al. Emphysema presence, severity, and distribution has little impact on the clinical presentation of a cohort of patients with mild to moderate COPD. Chest. 2011; 139 (1): 36-42.
8. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60 (11): 925-931.
9. Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009; 103 (5): 692-699.
10. Alfageme I, Reyes N, Merino M, et al. The effect of airflow limitation on the cause of death in patients with COPD. Chron Respir Dis. 2010; 7 (3): 135-145.
11. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171 (6): 591-597.
12. Almagro P, Calbo E, Ochoa de Echagüen A, et al. Mortality after hospitalization for COPD. Chest. 2002; 121 (5): 1441-1448.
13. Sanjaume M, Almagro P, Rodríguez-Carballeira M, Barreiro B, Heredia JL, Garau J. Post-hospital mortality in patients re-admitted due to COPD. Utility of BODE index [in Spanish]. Rev Clin Esp. 2009; 209 (8): 364-370.
14. Almagro P, Salvadó M, Garcia-Vidal C, et al. Recent improvement in long-term survival after a COPD hospitalisation. Thorax. 2010; 65 (4): 298-302.
15. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010; 182 (3): 325-331.
16. Miller MR, Hankinson J, Brusasco V, et al ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005; 26 (2): 319-338.
17. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54 (7): 581-586.
18. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47 (11): 1245-1251.
19. Cox DR, Oakes D. Analysis of Survival Data. London, England : Chapman & Hall; 1984.
20. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23 (13): 2109-2123.
21. Martínez-Camblor P, Corral N. A general bootstrap algorithm for hypothesis testing. J Statist Plann Inference. 2012; 142 : 589-600.
22. Hurst JR, Vestbo J, Anzueto A, et al Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363 (12): 1128-1138.
23. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary dis ease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009; 374 (9696): 1171-1178.
24. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009; 10 : 59.
25. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011; 140 (2): 331-342.
26. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009; 34 (3): 648-654.
27. Rennard SI, Calverley P. Rescue! Therapy and the paradox of the Barcalounger. Eur Respir J. 2003; 21 (6): 916-917.
28. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax. 2011; 66 (7): 585-590.
29. Almagro P, Cabrera FJ, Diez J, et al Working Group on COPD of the Spanish Society of Internal Medicine. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de Medicina Interna (ESMI) study. Chest. 2013; 142 (5): 1126- 1133.
30. Mannino DM, Diaz-Guzman E. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest. 2012; 141 (1): 73- 80.
31. López-Campos JL. Treatment strategies in chronic obstructive pulmonary disease: a proposal for standardization [in Spanish]. Arch Bronconeumol. 2010; 46 (12): 617-620.
32. Nagai A. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 3rd edition [in Japanese]. Nihon Rinsho. 2011; 69 (10): 1729-1734.
33. Grupo de Trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC). Arch Bronconeumol. 2012; 48 (suppl 1): 1- 83.